
What smart money is saying about Laurus Labs Limited
1 fund in our archive has pitched Laurus Labs Limited — most recently Baron India Fund in September 2026.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Get an email when a fund buys, sells or pitches it
Fund coverage · 1 thesis
- Baron India FundSeptember 2026
Laurus Labs is a leading Indian pharma company migrating from generic APIs to high-margin CDMO services, with expected 15-20% revenue and 20-25% earnings growth.
Read the full thesis
Read every full thesis on Laurus Labs Limited
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→